Monday, August 24, 2026 Never miss a recall or a rule change Go Pro · $20/mo →
Inside MedSpa
FDA Recall & Compliance Alerts for Medspa Owners
RegulatoryAbbVie Launches Phase 2 Forehead Lines StudytodayMarketFacial Rejuvenation Market Forecast to Hit $5.66B by 20302 days agoBusiness & M&AAllergan Aesthetics Overhauls Loyalty ProgramtodayDevices & TechXERF Technology Enters Australian Market for Skin Tightening2 days agoBusiness & M&AEvolus Expands Estyme to Canada, Australia, New ZealandtodayMarketArm Fat Now Top Body Sculpting Concern in Singapore2 days agoDevices & TechSofwave Hits One Million Treatments MilestonetodayRegulatoryCKD Bio Pursues China Botox Approval—2027 Launch Targeted2 days agoRegulatoryRevance Wins FDA Nod for Under-Eye InjectablesyesterdayMarketGLP-1 Pill Era Is Forcing Beauty Market ShiftyesterdayInjectablesAEON Releases Expanded ABP-450 Botox Biosimilar DatayesterdayDevices & TechUltherapy PRIME Real-Time Imaging Reshapes Midface Liftingyesterday
Trade & Tariffs

Section 301

The trade tool for retaliating against unfair foreign practices, the legal engine behind major China tariffs.

Also known as: Section 301 of the Trade Act, Unfair Trade Practices Tariffs

What it is
Section 301 of the Trade Act of 1974 lets the U.S. Trade Representative investigate and retaliate against foreign trade practices deemed unfair or discriminatory. Remedies include tariffs on targeted imports. It has been the basis for sweeping China tariff lists.
What it does
Section 301 actions target specific product lists, so investors read the lists to find exposed importers and advantaged domestic rivals. Exclusion processes and list revisions create ongoing catalysts. Supply-chain shifts follow as firms reroute sourcing.
The evidence
Section 301 China tariff lists reshaped sourcing decisions and pressured import-heavy sectors like consumer electronics and machinery.
Best for
China-import-exposed retailers and hardware names; domestic substitutes vary by list.
Pairs well with
tariff, section-232, export-controls
Use cautiously with
Exclusion grants and list changes can reverse exposure; treating a list as permanent misses the constant revisions.
Cautions
Tariff costs are often passed through or absorbed unevenly, so margin impact is company-specific.
General information, not medical advice. Ingredient effects vary by formulation, concentration, and skin. Patch-test new actives and consult a qualified provider before starting prescription ingredients.

Know what's coming before your patients ask for it.

New actives, device launches, and the FDA calls that change what you can offer — distilled into a two-minute brief, twice a week. Inside MedSpa Pro.

Go Pro · $20/mo
Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.
The twice-a-week intelligence brief Go Pro · $20/mo